Because the same genetic lesions leading to FGFR3-related skeletal disorders cause FGFR3-driven cancers (e.g., bladder tumors and multiple myeloma), FGFR inhibitors that have been investigated for FGFR3-driven cancers can be repurposed for the treatment of ACH. The gene discussed is FGFR3; the disease is plasma cell myeloma.